| Literature DB >> 22973305 |
Kristoffer Jönsson1, Gerd Gröndahl, Martin Salö, Bobby Tingstedt, Roland Andersson.
Abstract
Introduction. 60% of patients operated for colorectal liver metastases (CRLM) will develop recurrent disease and some may be candidates for a repeated liver resection. The study aimed to evaluate differences in intraoperative blood loss and complications comparing the primary and the repeated liver resection for metastases of colorectal cancer (CRC), as well as to evaluate differences in long-time follow-up. Method. 32 patients underwent 34 repeated liver resections due to recurrence of CRLM an studied retrospectively to identify potential differences between the primary and the repeat resections. Results. There was no 30-day postoperative mortality or postoperative hospital deaths. The median blood loss at repeat resection (1850 mL) was significantly (P = 0.014) higher as compared to the primary liver resection (1000 mL). This did not have any effect on the rate of complications, even though increased bleeding in itself was a risk factor for complications. There were no differences in survival at long-term follow-up. Discussion. A repeated liver resection for CRLM was associated with an increased intraoperative bleeding as compared to the first resection. Possible explanations include presence of adhesions, deranged vascular anatomy, more complicated operations and the effects on the liver by chemotherapy following the first liver resection. 30 out of 32 patients had only one reresection of the liver.Entities:
Year: 2012 PMID: 22973305 PMCID: PMC3437631 DOI: 10.1155/2012/568214
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Figure 1Kaplan-Meier estimate on survival following primary liver resection for colorectal liver metastases and reresection of the liver (n.s.).
Primary and repeated liver resection due to colorectal liver metastases—outcome data.
| Primary resection | Repeat resection |
| |
|---|---|---|---|
| Age | 66 ± 10 years | 64 ± 9 years | n.s. |
| Gender | 62% males | 59% males | n.s. |
| Bleeding | 1000 ± 1786 mL | 1850 ± 1833 mL | 0.014 |
| Length of stay | 8 ± 8 days | 8 ± 3 days | n.s. |
| Neoadjuvant chemo. administered | 33% | 31% | n.s. |
| Adjuvant chemo. administered | 39% | 36% | n.s. |
| Clavien grade II+ | 65% | 71% | n.s. |
| 2-year survival | 76% | 86% | n.s. |